Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA20(2) · pp.E97 · 2020
- 피인용
- Web of Science 4Scopus 4
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 2.298
- ISSN
- 2152-2650
저자
- 정기선제1저자Division of Hematology-Oncology, Departments of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
- Kim, KihyunDivision of Hematology-Oncology, Departments of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Kim, Hyo JungDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
- Kim, Sung HyunDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea
- Lee, Jeong-OkDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
- Kim, Jin SeokDivision of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea
- Eom, Hyeon-SeokHematology-Oncology Clinic, National Cancer Center, Goyang-si, Korea
- Min, Chang-KiDepartment of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 신호진교신저자Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
초록
For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016. Thalidomide plus a dexamethasone-based regimen is one of the treatment options for patients with relapsed/refractory MM, even after treatment with prior immunomodulatory agents, including thalidomide and lenalidomide. Background: For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016. We aimed to determine the efficacy of thalidomide plus dexamethasone-based regimens in patients with relapsed/refractory MM (RRMM). Patients and Methods: We conducted a multicenter retrospective analysis in Korea for patients with RRMM treated with thalidomide-based regimens who previously received bortezomib and immunomodulatory agents (IMiDs), including thalidomide and lenalidomide. Results: In 47 patients with RRMM, the median age was 64 years and the median number of previous treatment lines, including bortezomib and IMiDs, was 3. Primary resistance to bortezomib and lenalidomide was observed in 12 (26%) and 8 (17%) patients, respectively. The most common regimen was a combination of thalidomide, cyclophosphamide, and dexamethasone. The overall response rate was 38%; 2 patients (4%) experienced a complete response, and 2 patients (4%) experienced a very good partial response. The overall response rate of patients previously exposed to thalidomide was 53%. The median progression-free survival was 5.9 months, and overall survival was 9.2 months. Patients with disease that responded to the thalidomide-based regimen had better progression-free survival compared to those who did not (median, 8.8 vs. 2.5 months; P = .008). The most common adverse events were anemia (51%) for hematologic toxicities and peripheral neuropathy (30%) for non-hematologic toxicities. Conclusion: Thalidomide-based regimens are potential salvage treatment options for patients with RRMM, even those with disease with prior resistance to IMiDs. (C) 2019 Elsevier Inc. All rights reserved.
키워드
LenalidomideMultiple myelomaRefractoryRelapsedThalidomideLOW-DOSE THALIDOMIDEINITIAL THERAPYCOMBINATIONCYCLOPHOSPHAMIDETRANSPLANTATIONMULTICENTERDOXORUBICINMELPHALANCRITERIARELAPSE
식별자
- Scopus EID
- 2-s2.0-85076605353
- WoS UID
- 000513918800010



로그인
연구물 목록으로